New sedative may speed recovery for IBD patients during colonoscopy
NCT ID NCT07161297
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 35 times
Summary
This study compares two sedatives—remimazolam and midazolam—for colonoscopy in 200 adults with inflammatory bowel disease (Crohn's or ulcerative colitis). The goal is to see if remimazolam provides equal or better patient satisfaction and allows faster recovery. Participants receive one of the sedatives plus fentanyl, then rate their satisfaction and are checked for recovery speed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Humanitas Research Hospital
Rozzano, Milano, 20089, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.